A joint multidisciplinary team of researchers from the Chinese University of Hong Kong (CUHK), the University of Hong Kong (HKU), University College London, and Johns Hopkins University has developed an interactive, multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery aimed at treating patients with neurological diseases, such as brain tumours and Parkinson’s disease.
Singapore’s Health Sciences Authority recently approved axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) in adults after ≥2 lines of systemic therapy. Shedding light on this innovative therapy, Dr Matthew Frank, Assistant Professor of Medicine specializing in Blood and Marrow Transplantation and Cellular Therapy at Stanford University, Stanford, California, US, discussed landmark trial data, some real-world evidence, and their implications for patient selection and adverse event management during the Yescarta Commercial Launch in Singapore in May.
Biologic medicines are a category of very specific, highly effective medicines produced by a sophisticated and complex process involving living system1. Most of them are very large, complex molecules or mixtures of molecules, and many are produced using recombinant DNA technology. These medicines have revolutionised the treatment and prevention of many disabling and life-threatening diseases including cancers, Crohn’s disease, ulcerative colitis, diabetes, rheumatoid arthritis, osteoporosis, psoriasis, human immunodeficiency virus, multiple sclerosis, growth deficiencies, and more1.
Adjuvant treatment with pembrolizumab has significantly improved overall survival (OS) in patients with clear cell renal cell carcinoma (RCC) who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial presented at ASCO GU 2024.